Journal article
Fluvoxamine for the Early Treatment of COVID-19: A Meta-analysis of Randomized Clinical Trials
Abstract
Fluvoxamine is widely prescribed as an antidepressant. Recent studies show the drug may have a clinical benefit in treating COVID-19. We aimed to perform a meta-analysis of the existing randomized trials of fluvoxamine compared with placebo on the early treatment of COVID-19 patients. We included only randomized clinical trials enrolling ambulatory patients with early-stage disease (symptoms > 7 days) for the prevention of hospitalization. We …
Authors
Guo CM; Harari O; Chernecki C; Thorlund K; Forrest JI
Journal
American Journal of Tropical Medicine and Hygiene, Vol. 106, No. 5, pp. 1315–1320
Publisher
American Society of Tropical Medicine and Hygiene
Publication Date
March 9, 2022
DOI
10.4269/ajtmh.21-1310
ISSN
0002-9637